Benefit and risk of intravenous alteplase in patients with acute large vessel occlusion stroke and low ASPECTS

Gabriel Broocks, Rosalie McDonough, Matthias Bechstein, Uta Hanning, Caspar Brekenfeld, Fabian Flottmann, Helge Kniep, Marie Teresa Nawka, Milani Deb-Chatterji, Götz Thomalla, Peter Sporns, Leonard LL Yeo, Benjamin YQ Tan, Anil Gopinathan, Andreas Kastrup, Jens Fiehler, Lukas Meyer, for the German Stroke Registry – Endovascular Treatment (GSR-ET)

ABSTRACT

Background The benefit of best medical treatment including intravenous alteplase (IVT) before mechanical thrombectomy (MT) in patients with acute ischemic stroke and extensive early ischemic changes on baseline CT remains uncertain. The purpose of this study was to evaluate the benefit of IVT for patients with low ASPECTS (Alberta Stroke Programme Early CT Score) compared with patients with or without MT.

Methods This multicenter study pooled consecutive patients with anterior circulation acute stroke and ASPECTS≤5 to analyze the impact of IVT on functional outcome, and to compare bridging IVT with direct MT. Functional endpoints were the rates of good (modified Rankin Scale (mRS) score ≤2) and very poor (mRS ≥5) outcome at day 90. Safety endpoint was the occurrence of symptomatic intracranial hemorrhage (sICH).

Results 429 patients were included. 290 (68%) received IVT and 168 (39%) underwent MT. The rate of good functional outcome was 14.4% (95% CI 7.1% to 21.8%) for patients who received bridging IVT and 24.4% (95% CI 16.5% to 32.2%) for those who underwent direct MT. The rate of sICH was significantly higher in patients with bridging IVT compared with direct MT (17.8% vs 6.4%, p=0.004). In multivariable logistic regression analysis, IVT was significantly associated with very poor outcome (OR 2.22, 95% CI 1.05 to 4.73, p=0.04) and sICH (OR 3.44, 95% CI 1.18 to 10.07, p=0.02). Successful recanalization, age, and ASPECTS were associated with good functional outcome.

Conclusions Bridging IVT in patients with low ASPECTS was associated with very poor functional outcome and an increased risk of sICH. The benefit of this treatment should therefore be carefully weighed in such scenarios. Further randomized controlled trials are required to validate our findings.

INTRODUCTION

The application of intravenous alteplase is a standard of care for patients with acute ischemic stroke (AIS) presenting within 4.5 hours of symptom onset, as well as for patients with only subtle signs of lesion progression on baseline imaging. The clinical benefit of intravenous thrombolysis with alteplase (IVT) has been demonstrated in previous landmark trials. However, the effect of IVT on outcome in patients with large baseline ischemic cores who also undergo thrombectomy has not yet been thoroughly investigated.

The American Heart Association (AHA) specifically state that the application of alteplase is recommended in the setting of mild to moderately extensive early ischemic changes on CT, but should not be administered to patients whose CT brain imaging exhibits extensive regions of clear hypoattenuation. This recommendation is partly due to insufficient evidence for patients with extensive regions of clear hypoattenuation, making it difficult to define a specific threshold of acute hypoattenuation on non-enhanced CT (NECT) imaging for safe IVT administration, especially in the endovascular era. A potential harm of IVT may be of particular importance in bridging strategies considering the increasing number of patients with large ischemic cores (ie, low Alberta Stroke Programme Early CT Score—ASPECTS) that are currently enrolled in randomized trials (eg, TENSION, TESLA, IN EXTREMIS-LASTE, SELECT II, RESCUE-LIMIT) as part of this study. Therefore, the difficulty in differentiating between moderate and obvious hypoattenuation without the help of a validated threshold, together with the poor interrater reliability of ASPECTS rating, could result in varying policies for IVT administration in patients with low ASPECTS in the clinical routine, with a subsequent unknown impact on safety and functional outcomes.

The aim of this multicenter study was to investigate the impact of IVT in patients with an ASPECTS of 0–5 in clinical practice, that is, outside of randomized trials, and to compare the outcomes of patients receiving bridging IVT with those directly undergoing mechanical thrombectomy (MT). We hypothesized that bridging IVT before MT is associated with an improved functional outcome at the 90-day follow-up evaluation, with no associated significant increase in symptomatic intracranial hemorrhage (sICH).

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. Check for updates © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
METHODS

Study cohort

Patients enrolled in the German Stroke Registry—Endovascular Treatment trial (GSR-ET; ClinicalTrials.gov identifier: NCT03336392) treated between July 2015 and April 2018 were screened. The GSR-ET is an ongoing, open-label, prospective, multicenter registry of consecutively recruited patients who have undergone MT at 23 sites in Germany. A detailed description and the major outcome findings of the GSR-ET study design have been previously published. Additionally, three further tertiary stroke centers contributed patients receiving IVT and/or MT fulfilling the study inclusion criteria because the GSR-ET only includes patients with MT. A flow chart of patient inclusion can be found in the online supplemental material.

The a priori defined inclusion criteria for this study were (1) AIS due to anterior circulation large vessel occlusion, (2) CT-based diagnosis and treatment decision-making, (3) baseline ASPECTS of 0–5 assessed on NECT scan by a board certified neuroradiologist, (4) complete clinical baseline and outcome parameters, including the National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) score at day 90, (5) absence of intracranial hemorrhage and preexisting territorial thromboembolic infarctions on admission NECT. Baseline patient characteristics were retrieved from the medical records.

The study was conducted in accordance with the ethical guidelines of the local ethics committee and the Declaration of Helsinki. The leading ethic committee approved the GSR-ET. Additionally, approval from local ethics committees of the participating hospitals was obtained. Only anonymized data were analyzed. The requirement of informed consent was waived by ethics committees.

All patients who received IVT were compared with those who underwent direct MT without previous IVT with regard to functional outcomes and complications at the 90-day follow-up. A further outcome analysis was performed after stratification by the degree of recanalization following MT. Patients who received IVT before MT according to established guidelines were assembled into the bridging IVT group, while direct MT required the absence of IVT. The modified Thrombolysis in Cerebral Infarction (mTICI) scale was used to assess the degree of recanalization, with mTICI 2b–3 defined as successful recanalization. Good and very poor functional outcomes were defined as mRS 0–2, mRS 5–6, respectively. The mRS was evaluated at the 90-day follow-up by a physician or a trained and certified mRS nurse. The occurrence of sICH was defined according to the second European-Australasian Acute Stroke Study (ECASS II) as presence of intracerebral hemorrhage and a four-point neurological deterioration on the NIHSS.

Statistical analyses

Standard descriptive statistics were used for all presented data. For group comparison, Student t-tests (normal distribution) including CIs or SD and Mann-Whitney U tests (non-normal distribution) with interquartile range (IQR) were performed (table 1). The occurrence of sICH was analyzed and compared using χ² tests.

To determine the treatment effect of IVT on functional outcome and the occurrence of sICH, we used inverse probability weighted regression adjustments using logit outcome and treatment models adjusted for baseline and treatment variables (age, sex, NIHSS, ASPECTS, atrial fibrillation, time from onset to imaging, mTICI in a stepwise approach, and number of passes). Multivariable logistic regression models were generated using the same aforementioned independent variables. Subsequently, inverse probability weighted regression adjustments (IPWAs) and multivariable logistic regression were repeated excluding MT related variables: number of retrievals, and mTICI (replaced by MT) acknowledging that the implementation of mTICI and number of retrievals results in an exclusion of patients without MT (online supplemental material, online supplemental tables 3 and 4).

Good functional outcome (mRS 0–2), very poor functional outcome (mRS 5–6), and sICH served as the dependent variables.

Subsequently, we investigated the impact of vessel recanalization status and number of retrieval attempts on functional outcome separately for patients with and without IVT. A subgroup analysis of patients with ASPECTS 0–4 was performed. Finally, a subgroup analysis including patients with ASPECTS 3–5 was performed to investigate the impact of bridging IVT versus direct MT on outcome in an effort to reduce a possible selection bias regarding patients initially presenting with extensive signs of ischemia (ASPECTS 0–2) and for comparability with the protocols of ongoing trials (online supplemental material).

The significance level was set at p<0.05. Statistical analyses were carried out using Medcalc (version 11.5.1.0; Mariakerke, Belgium) and Stata/SE 13.0 (StataCorp, College Station, TX, USA)

Data availability statement

The data that support the findings of this study are available on reasonable request after approval of the ethics committee and all participating centers.

RESULTS

Study cohort

A total of 429 patients fulfilled the inclusion criteria. Patient characteristics are displayed in table 1. A flow chart diagram of patient inclusion can be found in the supplemental material (online supplemental figure 2).

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Patients’ baseline, procedural and outcome characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intravenous treatment with alteplase, n=290</td>
</tr>
<tr>
<td>Median age, years (IQR)</td>
<td>72 (60–79)</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>161 (56)</td>
</tr>
<tr>
<td>Median admission NIHSS (IQR)</td>
<td>19 (16–22)</td>
</tr>
<tr>
<td>Median ASPECTS (IQR)</td>
<td>4 (3–5)</td>
</tr>
<tr>
<td>Median time from onset to imaging, minutes (IQR)</td>
<td>119 (78–156)</td>
</tr>
<tr>
<td>MT, n (%)</td>
<td>90 (31)</td>
</tr>
<tr>
<td>mTICI 2b–3, n (%)</td>
<td>68 (76)</td>
</tr>
<tr>
<td>sICH, n (%)</td>
<td>37 (13)</td>
</tr>
<tr>
<td>Median mRS at 90 days, (IQR)</td>
<td>5 (4–6)</td>
</tr>
<tr>
<td>mRS 0–2, n (%)</td>
<td>43 (15)</td>
</tr>
<tr>
<td>mRS 5–6, n (%)</td>
<td>168 (58)</td>
</tr>
<tr>
<td>Mortality, n (%)</td>
<td>99 (34)</td>
</tr>
</tbody>
</table>

*Indicates significance. ASPECTS, Alberta Stroke Programme Early CT Score; mRS, modified Rankin Scale; MT, mechanical thrombectomy; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage.

Figure 1 Proportion of patients with sICH (symptomatic intracerebral hemorrhage; left) according to treatment with intravenous thrombectomy with alteplase (IVT) and mechanical thrombectomy (MT), and proportion of patients with good functional outcome, defined as a modified Rankin Scale score (mRS) 0–2 at day 90 (right). Points/brackets indicate means and 95% confidence intervals.

The median ASPECTS was 4 (IQR 3–5), the median time from symptom onset to imaging was 119 min (IQR 79–157 min), and the median NIHSS was 18 (IQR 15–22). A total of 290 patients (68%) received IVT and 168 patients (39%) underwent MT. Of these, 90 (21%) received IVT before MT, while 78 (18%) underwent direct MT. Sixty-one patients (14%) received neither IVT nor MT and 200 patients (47%) received IVT only. Sixty-four patients showed good functional outcome at day 90 (15%), 112 patients had a 3-month mRS score of 3–4 (26%), and 253 patients were assigned an mRS score of 5–6 (59%). A total of 164 untreated patients, while the rate of sICH for IVT-direct MT (17.8% vs 6.4%). No cases of sICH were observed in patients with bridging IVT compared with those undergoing direct MT (14.7% vs 3.7%). Conversely, in patients without successful recanalization, IVT application resulted in similar outcomes (mean mRS 4.9; 95% CI 3.8 to 5.0) at day 90. The rate of sICH was higher in patients with bridging IVT and first pass mTICI 2–3 (mean mRS 3.1, 95% CI 2.3 to 3.9). Patients with bridging IVT and first pass mTICI 2–3 had a correspondingly worse mRS score (mean 4.4, 95% CI 3.8 to 5.0) at day 90. The rate of sICH was higher in patients with bridging IVT with mTICI ≥2b–MT compared with direct MT (14.7% vs 3.7%). Conversely, in patients without successful recanalization, IVT application resulted in similar outcomes (mean mRS 4.9; 95% CI 4.1 to 5.6) compared with patients without IVT (mean mRS 4.8; 95% CI 4.1 to 5.6). A detailed presentation of the subanalysis can be found in the supplemental material (online supplemental table 1).

Subanalysis including patients with ASPECTS 0–4 A total of 268 patients (63%) evidenced an ASPECTS of 0–4 on baseline CT. In this patient cohort, IVT was independently associated with sICH in multivariable logistic regression analysis utilizing the aforementioned model (adjusted OR (aOR) 4.57, 95% CI 1.29 to 16.09, p=0.02). In contrast, a higher degree of reperfusion was associated with lower probability for sICH (aOR per mTICI 0.49, 95% CI 0.28 to 0.87, p=0.02). Regarding functional outcome (ie, mRS 0–2), IVT was no significant predictor (aOR 0.65, 95% CI 0.16 to 2.64, p=0.55), while
Figure 2 Multivariable logistic regression analysis displaying the impact of age (x axis) according to the application of intravenous alteplase (IVT; blue/red) on functional outcome with 95% CIs including all patients. mRS, modified Rankin Scale.

Figure 3 Multivariable logistic regression analysis displaying the impact of IVT (intravenous thrombolysis; blue/red) and ASPECTS (Alberta Stroke Programme Early CT Score; x axis) on the probability of sICH (symptomatic intracranial hemorrhage; y axis) including all patients.

a higher degree of reperfusion was independently associated with better outcomes (aOR 2.88, 95% CI 1.09 to 7.61, p=0.03). Further predictors of functional outcome were age (aOR 0.87, 95% CI 0.79 to 0.95, p=0.002) and NIHSS (aOR 0.87, 95% CI 0.78 to 0.98, p=0.02). A subanalysis only including patients with an ASPECTS of 3–5 is shown in the supplemental material.

DISCUSSION

This international, real-world observational multicenter study investigating the impact of IVT on patients with AIS and low ASPECTS revealed the following main findings: (1) bridging IVT was independently associated with the occurrence of sICH and (2) very poor functional outcome at day 90 (figure 3); (3) in patients with successful reperfusion after MT, higher frequencies of sICH and lower rates of good functional outcome were observed in patients with bridging IVT, (4) the best functional outcome rates were observed in patients who underwent direct MT with a successful first pass mTICI 2b–3 reperfusion.

This multicenter study aimed to investigate the impact of IVT in patients with low ASPECTS in the context of MT by comparing the functional outcomes of patients with direct MT versus those with bridging IVT, only including patients with CT as the primary imaging modality. The choice of imaging modality in the evaluation of treatment effects in extensive baseline stroke may be of high importance considering that in the HERMES meta-analysis, a benefit of MT in patients with low ASPECTS was only observed after MRI-based inclusion.23 24 In contrast, no treatment effect for CT-selected cases was observed, which also highlights that CT-based versus MRI-DWI-based ASPECTS have a poor inter-modality agreement,35 which explains substantial differences in outcome prediction.6 26 27

Although numerous studies investigating the relationship between signs of early ischemia and response to IVT exist, these data are mainly derived from the pre-thrombectomy era.28–30 In addition, the study protocols of previous IVT landmark trials were heterogeneous with regard to the treatment of early ischemic changes and often excluded patients who showed early extensive signs of ischemia. For example, the ECASS trial specifically excluded patients with signs of ischemia in more than a third of the MCA territory, which can be translated to an ASPECTS of ≤7.31 32 A post hoc analysis of the ECASS study showed that the extent of hypoattenuation on the initial CT is predictive of the response to IVT.7 33 The authors of the IST-3 trial concluded that their study might not have had enough statistical power to ascertain whether alteplase treatment in patients with an ASPECTS of 0–7 was of clinical benefit, although early ischemic changes were observed to be associated with reduced functional independence at 6 months and an increased risk of symptomatic hemorrhage. This relationship between early ischemic changes and the occurrence of secondary hemorrhage has been corroborated by other IVT studies.30 Accordingly, we observed lower rates of sICH in patients with direct MT (6.4%) compared with those treated either with IVT only (10.4%) or bridging IVT (17.8%). The lowest rates of sICH (3.7%) were found in the subgroup of direct successful MT, significantly lower compared with successful MT with bridging IVT (14.7%). Because the occurrence of sICH after stroke is strongly correlated with very poor outcome, these findings suggest that IVT may carry a substantial harmful treatment effect in the subgroup of patients with low ASPECTS, especially if administered before MT.34

The majority of patients included in the thrombectomy landmark trials received IVT, ranging from 72% to 100%.27 Recently, the DIRECT-MT study, the first of several ongoing direct to MT randomized controlled trials, reported non-inferiority of direct MT compared with MT preceded by IVT within 4.5 hours after stroke onset, despite the formal non-inferiority margin being relatively high at 20%.35 Similarly, direct MT met the predefined thresholds for non-inferiority for the outcome at 90 days in the SKIP and DEVT trial,36 37 with similar rates of reperfusion (mTICI 2b–3: 88.5% vs 87.2% after bridging) and similar mRS scores (mRS 0–2: 54.3% vs 46.6% after bridging).38 More lately, a meta-analysis of randomized controlled trials indicated a non-inferiority of direct MT with a 4% margin of confidence.39 However, there is still a lack of data on direct MT versus bridging IVT in patients with lower ASPECTS. The SKIP trial specifically excluded patients with ASPECTS 0–5, while the study protocol of DIRECT-MT does not include ASPECTS as a selection variable. However, the IQR in both patient groups in the DIRECT-MT cohort was 7–10, strongly indicating the ASPECTS distribution of the included subjects. The DEVT trial also considered patients with all ASPECTS, but the median ASPECTS was 8 (IQR 7–9) in both groups, also indicating the lack of patients with low ASPECTS.37 SWIFT DIRECT (NCT03192332) specifically excluded patients with an ASPECTS 0–3, and is hence also
expected to represent mainly cases with higher ASPECTS. A recent retrospective study observed that bridging IVT was associated with increased risk of sICH, but this study included patients mainly based on MRI as the primary imaging modality; this is an important limitation in contrast to the present study, which only includes patients with CT imaging at baseline.39 In line with this study, we also observed a trend towards improved functional outcomes in this subgroup of patients. Highlighting the possible effectiveness of MT in patients with large baseline infarcts (ie, low ASPECTS), we observed the most favorable results for the subgroup who underwent successful mTICI 2b–3 without treatment (BMT). The lower bar graphs show outcome for patients with successful MT after the first pass (mTICI 2b–3) for all direct MT patients, MT patients who received bridging IVT, and IVT only includes patients with CT imaging at baseline.39 In line with this study, we also observed a trend towards improved functional outcomes in this subgroup of patients. Highlighting the possible effectiveness of MT in patients with large baseline infarcts (ie, low ASPECTS), we observed the most favorable results for the subgroup who underwent successful mTICI 2b–3 without previous IVT (mean mRS 3.9, 95% CI 3.4 to 4.4). This was especially present in cases with fewer retrieval attempts (OR 0.62, 95% CI 0.41 to 0.92, p=0.02) or first pass mTICI 2b–3 (mean mRS 3.1, 95% CI 2.3 to 3.9). IVT, however, was a significant predictor of very poor outcome, together with advanced age, as previously reported.40

Table 2  Multivariable logistic regression analysis for independent predictors of very poor outcome (modified Rankin Scale (mRS) 5–6) at 90-day follow-up

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All patients</th>
<th>MT patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>1.07</td>
<td>1.09</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>0.82</td>
<td>0.75</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>1.11</td>
<td>0.87</td>
</tr>
<tr>
<td>NIHSS on admission</td>
<td>1.02</td>
<td>1.04</td>
</tr>
<tr>
<td>ASPECTS on admission</td>
<td>0.78</td>
<td>0.88</td>
</tr>
<tr>
<td>Intravenous thrombolysis</td>
<td>1.68</td>
<td>2.22</td>
</tr>
<tr>
<td>mTICI score after thrombectomy†</td>
<td>X</td>
<td>0.63</td>
</tr>
<tr>
<td>Number of passages†</td>
<td>X</td>
<td>1.21</td>
</tr>
</tbody>
</table>

*Indicates significance.
†Excluded variables to incorporate all patients.

Figure 4 Bar graph showing the distribution of modified Rankin Scale (mRS) scores at 90 days according to the application of intravenous alteplase (IVT) and mechanical thrombectomy (MT). The upper bar graphs show outcome for patients with endovascular treatment (EVT) vs without treatment (BMT). The lower bar graphs show functional outcome for patients with successful MT after the first pass (mTICI 2b–3) for all direct MT patients, MT patients who received bridging IVT, BMT patients with and without IVT, respectively.

According to the current AHA guidelines, the application of alteplase is recommended ‘in the setting of early ischemic changes on CT of mild to moderate extent’. However, IVT is not recommended in patients with extensive regions of ‘clear hypoattenuation’.41 This highlights a twofold problem: (1) how can early hypoattenuation of moderate extent be safely distinguished from clear hypoattenuation in the absence of any objectifiable threshold, (2) how high is the impact of the known poor inter-rater reliability of early ischemic changes and does this in turn lead to substantial differences in the decision-making for or against IVT in patients with low ASPECTS in daily clinical practice?13 42 More importantly, the uncertain impact of IVT in patients with low ASPECTS may affect outcomes of the currently ongoing trials on MT in patients with low ASPECTS, to the extent of potentially even causing failure of these trials. Therefore, the standardized application of IVT in patients with low ASPECTS should be further evaluated, in particular in light of the availability of better treatment selection tools.43 First, the scoring of ASPECTS could be improved by the use of standardized automated tools that are already available and are known to be precise in their prediction of the true final infarct volume compared with subjective ASPECTS reading.44–46 Second, objective quantitative parameters could complement ASPECTS, such as quantitative lesion water uptake.47–49 Indeed, it is important to note that the ASPECTS rating itself is based on binary subjective rating criteria (hypoattenuation yes/no). Therefore, it does not further quantify the degree of hypoattenuation. Early infarct of brain tissue is defined by net water uptake which, in turn, is directly related to lesion hypodensity and volume increase (ie, extracellular edema). The physics behind the decrease of CT attenuation of ischemic tissue requires a net influx of water (ie, edema), which has been illustrated in previous in vitro and in vivo experiments.49 Therefore, such an additional quantitative parameter could improve the interpretation of the current guidelines in the more accurate differentiation of early ischemic hypoattenuation from frank hypodensity to better select patients with low ASPECTS for IVT administration. Furthermore, the specific degree of hypoattenuation could be predictive of the response to IVT in patients with low ASPECTS or could be used as a tool for early risk estimation of sICH.47 50
Limitations

Based on the retrospective design and the absence of randomization, several sources of potential bias have to be considered. The decision of whether to apply IVT or not was left to the discretion of the treating physician. The present study did not analyze center-specific differences in IVT application, which might constitute a bias with regards to different institutional guidelines. Even in the absence of significant differences between the different cohorts in our analysis, we cannot rule out smaller differences that may have been obscured by the limited sample size. Moreover, without randomization, unknown risk factors for a poor outcome are not accounted for. Furthermore, no follow-up vessel imaging was available to compare the impact of reperfusion in the best medical treatment cohort.

CONCLUSION

The application of IVT before MT in patients with low ASPECTS was associated with an increased risk of sICH and a higher likelihood for very poor functional outcome. Therefore, IVT in extensive baseline infarctions should be considered with caution until evidence from randomized trials is available to support (or discredit) the application of IVT in this particular subgroup. Future research is necessary to identify objective selection criteria for IVT in patients with low ASPECTS.

Author affiliations

1Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3Department of Diagnostic and Interventional Neuroradiology, University Hospital Basel, Basel, Switzerland
4National University Health System and Yong Loo Lin School of Medicine, National University of Singapore, Singapore
5Department of Neurology, Klinikum Bremen-Mitte GmbH, Bremen, Germany
6Department of Neuroradiology, Klinikum Bremen-Mitte GmbH, Bremen, Germany
7National and Kapodistrian University of Athens, Aretaiio Hospital, Athens, Greece
8Department of Neuroradiology, UKGM, Marburg, Germany

Twitter Jens Fieler @Feie015

Contributors

GB, MB, UB, CB, FF, JF, AK, LM have contributed to conception and design of the study. GB, RMD, HK, MTN, MDC, PS, LLLY, BYQT, AG, AK, MP, PP, JF, LM have contributed to acquisition and analysis of data. GB, RMD, FF, MTN, JF, AK, LM have contributed to drafting a significant portion of the manuscript. GB serves as a guarantor of this study and accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

JF: research support from the German Ministry of Science and Education (BMBF), German Ministry of Economy and Innovation (BMWWi), German Research Foundation (DFG), European Union (EU), Hamburgische Investitions-/Förderbank (IFB), Medtronic, Microvention, Philips, Styker; consultancy appointments; Acandis, Bayer, Boehringer Ingelheim, Cerenovus, Covidien, Evac Vascular, MD Clinicals, Medtronic, Medina, Microvention, Penumbra, Route92, Stryker, Transverse Medical; stock holdings for Tegus. Editorial Board member at JNIS. GT reports receiving consulting fees from Acandis, grant support and lecture fees from Bayer, lecture fees from Boehringer Ingelheim, Bristol-Myers/Squibb/Pfizer, and Daiichi Sankyo, and consulting fees and lecture fees from Portola and Stryker. LLVY has received research support from National Medical Research Council (NMRC), Singapore and research support from Ministry of Health (MOH), Singapore. Consultancy from Stryker, J&B, See-mode. Stock holdings for Cerecolo. PP is consultant for Penumbra and Ab Medica.

Patient consent for publication

Not applicable.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data are available upon reasonable request. Data are available upon reasonable request to the corresponding author.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Gabriel Broocks http://orcid.org/0000-0002-7575-9850
Matthias Bechstein http://orcid.org/0000-0002-5652-7499
Uta Hannig http://orcid.org/0000-0002-7543-8555
Fabian Flottmann http://orcid.org/0000-0001-8358-8089
Helge Kniep http://orcid.org/0000-0001-5258-2370
Marie Teresa Nawka http://orcid.org/0000-0001-7423-9725
Leonard LL Yeo http://orcid.org/0000-0002-4249-0402
Andreas Kastrop http://orcid.org/0000-0003-2766-2293
Jens Feieler http://orcid.org/0000-0001-8533-7478
Lukas Meyer http://orcid.org/0000-0002-3776-638X

REFERENCES

Ischemic stroke


